Investment and operating platform focused on bringing
science-based innovations in nutraceuticals and
cosmeceuticals to a commercial stage. It takes active positions
into start-ups with a combination of cash investments and
in-kind work realized by our group service companies:
Compound Discovery & Optimization (NEEM), Formulation & Product Development (INQPHARM), Clinical Trials & Regulatory Optimization (Analyze&Realize), Financial Structuring &
Distribution (Hyperbolic Holdings).
www.faunasystems.com COMING SOON
Fauna Systems is a platform that designs, develops and manufactures Xenobot and Anthrobot solutions for a variety of high impact applications in industry, human and animal health. Xenobots and Anthrobots are living multicellular organisms that are designed from scratch and optimized for specific functions, body shapes and behaviors via advanced artificial intelligence techniques.
Early screening and vaccines platform based on massively parallel detection of cancer immune signatures stemming from RNA transcriptional errors.
Prognostic methodology for infectious and autoimmune disease severity based on differential gene expression.
Self-learning controller system and algorithm for provision of insulin to diabetics, designed for automated iCGM mode or manual use.
Autologous regenerative medicine treatment of diabetes mediated by transplantation of beta-islet-like cells reprogrammed from patient’s blood cells.
Molecular diagnostics platform based on non-dimerizing primers for PCR, with applications to detection of infectious diseases, liquid biopsies, crop genetics and next generation sequencing.
Diagnostics and therapeutics based on efficient detection and inhibition of the Focal Adhesion Kinase pathway, with applications to metastatic-prone cancers and fibrosis induced by cancer, wound or stress.